GlobeNewswire
-
Regional Health Properties Reports Third Quarter 2026 Results
16/11/2026 -
Pear Health Labs Launches Pear Health Companion, an Agentic AI Platform for Health Plans and Providers
16/11/2026 -
Vivani Medical Announces Private Placement Equity Financing
16/11/2026 -
Rakovina Therapeutics to Present ATR Inhibitor Data in PTEN-Deficient Prostate Cancer at the 38th EORTC-NCI-AACR Symposium
16/11/2026 -
Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
16/11/2026 -
Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients
16/11/2026 -
Zymeworks Announces $200 Million Share Repurchase Authorization
16/11/2026 -
Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology
16/11/2026 -
Alamar Biosciences Highlights NULISA Data in 46 Presentations at CTAD 2026, Including 10 Oral Presentations
16/11/2026 -
Transactions under Novonesis’ share buyback program
16/11/2026 -
CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
16/11/2026 -
Medline Inc. announces launch of secondary offering of Class A common stock
16/11/2026 -
Bioxytran Turns Science into Everyday Wellness with Launch of Its First Two Nutraceutical Products
16/11/2026 -
Medicenna Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp Versus a Matched External Control at SNO 2026
16/11/2026 -
Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder
16/11/2026 -
Noom to Bundle a New Wearable, Noom Band, Into Its Popular Enterprise Obesity Care Programs at No Additional Cost
16/11/2026 -
Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
16/11/2026 -
Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results
16/11/2026 -
Apptly Health Technologies Announces Strategic Partnership with BioTrax AI to Bring Precision Longevity Tools to Its Physician Network
16/11/2026
Pages